Kiora Pharmaceuticals, Inc.

As of May 9, 2025, Kiora Pharmaceuticals is considered overvalued with a valuation score of -0.8451, despite a high ROCE of 1262.96%, negative P/E ratio, and a 15.86% decline in stock performance over the past year compared to a 10.26% gain in the S&P 500.

As of June 20, 2025, the trend is mildly bullish, supported by weekly and monthly MACD and KST indicators, despite some short-term weakness indicated by daily moving averages and mixed signals from Bollinger Bands and Dow Theory.

As of March 2022, the management team of Kiora Pharmaceuticals, Inc. includes Paul Chaney (Independent Chairman), Stephen From (CEO), Steven Boyd, Keith Maher, Morton Goldberg, Thomas Hancock, and Bernard Malfroy-Camine (all Independent Directors). They oversee the company's strategic direction and operations.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapeutics and drug delivery systems for eye diseases. It has a market cap of $8.95 million and reported a net profit loss of $2 million as of March 2025.

As of Jun 18, Kiora Pharmaceuticals, Inc. has a market capitalization of 8.95 million, with net sales of 0.02 million and a net profit of -12.04 million over the latest four quarters. The company reported shareholder's funds of 25.76 million and total assets of 36.48 million as of Dec 24.